Novo Nordisk begins phase 1 tests with the first oral insulin analogue
Madrid (11-12-09) .- Novo Nordisk has begun the first phase 1 trials with an oral insulin analogue (NN1952).This milestone will report 2 million dollars to the company Merrion Pharmaceuticals PLC, whose Gipet technology will be used in the NN1952 formulation.
The objective of the essay, which is being carried out in Germany, is to investigate the safety, tolerance, pharmacokinetics (drug exposure) and pharmacodynamics (effect) of NN1952 in holy volunteers and people with type 1 diabetes and type 2. The results of the results of theessay, in which about 80 people are placed to enroll, they are expected to be available in the first half of 2011.
News published in the interactive doctor, digital publication.